Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Zoledronic Acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 53 Prostatic Neoplasms 43 Neoplasm Metastasis 25 Multiple Myeloma 25 Pain 13 Osteoporosis 13 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Osteosarcoma 7 Lung Neoplasms 6 Carcinoma, Renal Cell 6 Neuroblastoma 5 Neoplasms, Plasma Cell 5 Humoral Hypercalcemia Of Malignancy 5 Fractures, Bone 4 Bone Diseases, Metabolic 4 Sarcoma, Ewing 3 Sarcoma 3 Lymphoma 3 Kidney Neoplasms 3 Bone Neoplasms 3 Bone Diseases 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Spinal Cord Compression 2 Small Cell Lung Carcinoma 2 Rhabdomyosarcoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pleural Effusion, Malignant 2 Ovarian Neoplasms 2

Interventions

Cyclophosphamide 21 blinatumomab 16 Cytarabine 14 fludarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Rituximab 7 Methotrexate 7 Dexamethasone 7 Daunorubicin 7 Lenalidomide 6 Vincristine 5 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Liquid Biopsy 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Cladribine 3 Chemotherapy, Adjuvant 3 Busulfan 3 Asparaginase 3 trastuzumab deruxtecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡